August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Wolfgang Miesbach: What Does Acquired Haemophilia A Truly cost, Clinically and Economically?

Wolfgang Miesbach/LinkedIn

May 17, 2026, 17:41

Wolfgang Miesbach: What Does Acquired Haemophilia A Truly cost, Clinically and Economically?

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“Real-world data from Munich – what does acquired haemophilia A truly cost, clinically and economically?

Great data presented at GTH2026 in Bonn by Seidl, Weiglein, Möhnle et al. from University Hospital LMU Munich – a retrospective single-center analysis of 51 adult AHA patients diagnosed between 2011 and 2023.

Patient characteristics:

Median age 76 years – elderly, multimorbid
Median FVIII activity 4% Median inhibitor titer 19 BU Median aPTT 72 sec
Median hospital stay 38 days | Median ICU stay 10.5 days
Etiology: 59% idiopathic, 27% autoimmune, 8% malignancy-associated, 6% postpartum

Clinical outcomes:

100-day mortality nearly 12%, 1-year mortality nearly 19%
Early deaths primarily bleeding- and infection-related
Severe bleeding (EACH2) independently associated with reduced overall survival (p is equal to 0.002)
Low baseline FVIII activity independently predicted worse outcomes

Treatment reality:

43% steroids alone – but 57% needed combination immunosuppression

Emicizumab used for bleeding prophylaxis in 5 patients (9.8%)

The cost dimension for the period 2011-2023:

Median in-hospital drug costs: €130,069 per patient

More than 95% driven by bypassing agents and factor replacement”

Other posts featuring Wolfgang Miesbach on Hemostasis Today.